Table 3.
Clinical characteristics of patients treated with TAE + OK-DC and TAE alone.
| TAE + OK-DC | TAE | P | |
|---|---|---|---|
| No. of patients | 13 | 22 | |
| Age (years) | 68.2 ± 9.1 | 70.0 ± 7.6 | n.s.† |
| Gender (M/F) | 9/4 | 13/9 | n.s.‡ |
| White cell count (×102/µl) | 34.4 ± 11.6 | 41.4 ± 18.9 | n.s.† |
| Lymphocytes (×102/µl) | 10.4 ± 3.6 | 12.4 ± 4.7 | n.s.† |
| Platelets (×104/µl) | 11.5 ± 10.2 | 10.3 ± 5.8 | n.s.† |
| Hepaplastin test (%) | 64.6 ± 11.6 | 75.5 ± 24.3 | n.s.† |
| ALT (IU/l) | 56.7 ± 38.9 | 67.9 ± 44.6 | n.s.† |
| Total bilirubin (mg/dl) | 1.3 ± 0.7 | 1.1 ± 0.6 | n.s.† |
| Albumin (g/dl) | 3.4 ± 0.6 | 3.6 ± 0.4 | n.s.† |
| Non-cancerous liver parenchyma (no.) | |||
| Chronic hepatitis | 0 | 8 | |
| Cirrhosis (Child–Pugh A/B/C) | 13 (5/8/0) | 14 (6/8/0) | n.s.‡ |
| TNM stages (I/II/III/IV-A/IV-B) | 0/4/9/0/0 | 3/8/11/0/0 | n.s.‡ |
| No. of tumours | 2.5 ± 1.3 | 1.9 ± 1.3 | n.s.† |
| Largest tumour (mm) | 30.2 ± 9.4 | 32.6 ± 15.2 | n.s.† |
| AFP | 204.8 ± 404.1 | 201.8 ± 544.2 | n.s.† |
Results are expressed as means ± standard deviation.
†
Mann–Whitney U-test.
‡
Fisher's exact test. TAE, transcatheter arterial embolization; OK-DC, OK432-stimulated dendritic cells; ALT, alanine transaminase; TNM, tumour–node–metastasis; AFP, alpha-fetoprotein; Child–Pugh, Child–Pugh classification; n.s., not significant.